MTA2 antibody - middle region (ARP35743_P050)
- Known as:
- MTA2 (anti-) - middle region (ARP35743_P050)
- Catalog number:
- arp35743_p050
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- MTA2 antibody - middle region (ARP35743_P050)
Related genes to: MTA2 antibody - middle region (ARP35743_P050)
- Gene:
- MTA2 NIH gene
- Name:
- metastasis associated 1 family member 2
- Previous symbol:
- MTA1L1
- Synonyms:
- MTA1-L1
- Chromosome:
- 11q12.3
- Locus Type:
- gene with protein product
- Date approved:
- 1999-05-17
- Date modifiied:
- 2016-10-05
Related products to: MTA2 antibody - middle region (ARP35743_P050)
Related articles to: MTA2 antibody - middle region (ARP35743_P050)
- Lamotrigine, a clinically approved anticonvulsant, has recently gained interest for its potential anticancer effects. However, the molecular mechanisms underlying its activity in breast cancer remain poorly understood. Here, an integrated mass spectrometry-based proteomic strategy combining data-independent acquisition (DIA) and thermal proteome profiling (TPP) was applied to investigate the cellular effects and potential targets of lamotrigine in the human breast cancer cell line MCF-7. The DIA-based quantitative approach identified 6622 proteins, of which 142 were significantly modulated following lamotrigine exposure. Differentially expressed proteins were mainly associated with mitochondrial energy metabolism, chromatin organization, and protein translation. TPP experiments identified significant thermal stability alterations in ABRAXAS2, MT-CYB, TMEM97, and MTA2 upon lamotrigine treatment. Notably, both DIA and TPP analyses highlighted mitochondrial alterations, with consistent involvement of MT-CYB, suggesting mitochondrial dysfunction as a potential central mechanism of lamotrigine's action. Overall, these findings characterize proteome-level alterations induced by lamotrigine and support its further evaluation in breast cancer. - Source: PubMed
Publication date: 2026/05/20
Giuliano AnnaritaRicci ElenaGabriele CaterinaFava MariarosaSpadafora SofiaMorelli CatiaSisci DiegoGaspari Marco - Current multiple myeloma (MM) risk stratification, anchored on the Revised International Staging System (R-ISS), provides a static snapshot of disease but fails to capture its dynamic biological evolution, functional tumor-microenvironment crosstalk, and real-time treatment response. Mass spectrometry (MS)-based proteomic and metabolomic profiling has emerged as a high-sensitivity tool for both novel biomarker discovery and minimal residual disease (MRD) monitoring. This systematic review evaluates the independent prognostic value and clinical utility of quantitative MS-based proteomics and metabolomics compared to standard-of-care risk models and traditional disease monitoring techniques. - Source: PubMed
Publication date: 2026/04/22
Moursy NaseelSiraj HibbaNasir ZainabTanweer AffafSajid Muhammad Raihan - Cellular membranes serve as selective barriers, and membrane permeability is crucial for drug pharmacokinetics. While in vitro and in vivo methods exist, predicting and designing membrane permeability remains challenging. We developed a thermodynamics-based deep learning framework to analyze the structure-permeability relationship, based on the concept that interactions between membrane lipids and small molecules influence permeability. We determined the membrane penetration thermodynamics of 8,239 compounds using coarse-grained molecular dynamics simulations and created interpretable graph neural network models to predict and design drug membrane permeability. As a proof-of-concept, we designed a novel nasal-administered melatonin analog, MT-A2, optimized for permeability. Compared with melatonin, MT-A2 showed superior nasal absorption, prolonged brain retention, and enhanced sleep efficacy. Our results provide a promising approach for predicting and designing membrane permeability, aiding in the development of drugs with better pharmacokinetics. - Source: PubMed
Publication date: 2026/04/06
Ma ZhenyuNiu MengyingSong YuyangZhang LeiWang WenxinWang TengfeiZhu JingyiYang ChunyiXu LimeiWu XiuyunXiao MinZuo RonghuaLi YitongGuo XiangyangZheng ShengyangXu YuwenWang LushanLi JianLi ZhengqianJiang Xukai - - Source: PubMed
Zhao LGuo HZhou BFeng JLi YHan TLiu LLi LZhang SLiu YShi JZheng D - Chromatin is essential for eukaryotic life. Tens of thousands of chromatin regulator (CR) proteins exist in eukaryotic genomes that are predicted to modulate chromatin states; however, their molecular functions remain largely untested experimentally. Here, we construct a library of over 300 full-length CRs from humans, plants, yeast, protozoa, and virus, each fused to DNA-binding domains, and test their direct effect on transcriptional repression and activation in plants and human cells. We discover CRs with cross-kingdom functionality when transferred across eukaryotes, including CRs that outperform existing tools for programmable transcriptional repression and activation in plants and human cells. Using pooled CRISPR screens, we demonstrate a suite of CRISPR repressors that titrate gene expression at intermediate levels. Finally, we identify RCOR1 and MTA2 as universal eukaryotic repressors that retain repressive activity in plants, yeast, and human cells. Our toolkit advances synthetic eukaryotic engineering and expands our understanding of CR functionality across eukaryotes. - Source: PubMed
Publication date: 2026/02/11
Ornelas Izaiah JOwens Lauren AAlamos SimonHummel Niklas F CHernández Zamora Mitzi GPhan Ngan TPattali Rithu KShih Patrick MNuñez James K